ConferenCe

ww

w.fl

emin

g.ev

ents

16 & 17 May 2018 | Amsterdam

3rd A

nnua

l

Patient Engagement & Experience

Partnering to improve real-world outcomes that matter to patients

Expert Advisory Board

Your prestigious speaker panel

Søren Skovlund, DenmarkChief Patient Officer, DrugstarsSenior Research Scientist, Aalborg University, Denmark

Lode Dewulf, BelgiumFormer Chief Medical Affairs Officer and Chief Patient Affairs Officer

Šarūnas NarbutasLithuanian Cancer Patient Coalition (POLA)President

Jason DeGoesTeva, NetherlandsSenior Vice President Global Patient Solutions

Matthew ReaneySanofi, UKHead of Patient Reported Outcomes

Przemyslaw KardasMedical University of Lodz, PolandHead of the Department Family Medicine

Andreas ChristodoulouEPF's Youth Group, CyprusPresident

Silvia BakkersJ&J, NetherlandsDirector Value-Based Healthcare

Robert ThomasCambridge University Hospitals, UKConsultant Oncologist

Ana Maria ArboledaTeva, SpainDirector of European Operations, Patient Solutions

Annamarie DillonProQR Therapeutics, NetherlandsSenior Director, Patient & Medical Community Engagement

Marleen KaateePSC Patients Europe, NetherlandsFounding President

Grainne CrowleyBiogen, BelgiumHead Patient Advocacy Europe & Canada(to be confirmed)

Wendy OlsderNetherlandsBoard Member of Youth-R-Well.com and representative of Young PARE

Jessica LeyguesCelgene, FrancePatient Associations and Patient Institutional Programs Manager

Veerle AertsenEUPATI Fellow, Belgium Co-chair and spokesperson for EupatiExpert Parkinson's Disease Patient

Martynas GedminasLithuaniaChairman Junior Doctors Association

Geoff RollasonPfizer, UKPatient Experience & Service Director Oncology

Alexandra MoutetUCB, Belgium Global Head of Patient Affairs

Stefan FlorentinusAbbVie, NetherlandsMedical DirectorChair of the project group at the Dutch Association of Innovative Medicine

Anna SzopaJ&J, PolandHead of Patient Engagement & Advocacy

Laura McKeaveneyNovartis, SwitzerlandGlobal Head Patient Advocacy

Vanessa FerreiraSanthera, SwitzerlandHead Patient Advocacy Europe

Ruth WilsonTeva, NetherlandsGlobal Head of Patient Advocacy

www.fleming.events tel.: +421 257 272 232 email: monica.jones@fleming.events

Key topics effective methods and tools for patient engagement evidence-based strategies for patient activation and

motivation Maximizing patient experience across the health care

continuum Building and deploying sustainable patient support

programmes Multi-stakeholder collaboration for people-centred

healthcare Patient-centric use of digital health, big data analytics

and mobile technologies

Special features HCPs, Patients, Payers, Government,

Pharmacists and Industry under one roof

360 Multi-stakeholder Breakout Discussions

On-stage interview

Patient Engagement Panel

Keys to overcome legal, compliance and regulatory challenges for effective patient engagement

Best practices to partner with payers and patient advocacy groups

Increasing patient voice in decision making Tips for patient activation Applying evidence to real-world settings Measuring patient outcomes and the business value

of patient support programs next steps to achieve an integrated approach to

patient support strategy in a fragmented multi-stakeholder environment

Innovation in drug design and packaging for greater patient adherence

examples of tools for utilizing digital engagement Defining critical actions to maximize patient

experience Shaping the roles of different stakeholders to improve

patient outcomes Guiding patients through the complexity and variety

of different patient services

Key take-aways:

Søren E. Skovlund

'The “Patient Adherence and engagement” conference, organized in May 2017 in Amsterdam, provided a fantastic platform for collaborative discussion amongst internationally leading patient advocates, patient organizations, payers, pharma, regulators, health technology companies and adherence researchers.

The unique focus of this event was the convergence points for “patient adherence and patient engagement” - a focus which turned out to be very timely and appropriate for all involved.

We believe that the way forward is to define, strengthen and unify the field of multi-disciplinary scientific research for medicine optimization.

Let's meet again together with different stakeholders in May 2018 in Amsterdam to further establish the best wins that can be gained through partnering with patients as equal partners across the value chain to improve the real-world use of medicines.'

Remarks from the conference chairman:

www.fleming.events tel.: +421 257 272 232 email: monica.jones@fleming.events

DAY 116 May 2018

8:30 Registration & morning coffee

9:00 Welcoming note from Fleming.

9:05 Opening remarks from the chair

From adherence to improved patient outcomes

9:10 KICK-OFF PANEL: Defining the “burning platform”: A multi-stakeholder call to action to improve the real world use of medicines for better patient outcomes

•What is the urgent case for action across different stakeholders?

•Key factors influencing optimal real world use of medicines

•Discuss & define shared challenges, goals and expectations across stakeholders

PAnElIStS:

Silvia Bakkers, J&J, NetherlandsDirector Value Based HealthcareMarleen Kaatee, PSC Patients Europe, Netherlands, Founding PresidentAndreas Christodoulou, EPF's Youth Group, Cyprus, PresidentSøren Skovlund, Drugstars, DenmarkChief Patient Officer

9:40 KEYNOTE: How to embed patient-reported outcome measurements in a pragmatic way in value-based health care and what do we really want to achieve with it?

•Which ProMs are of what use to which patient and when? The threat of paralysis by analysis!

•Who else than the patient him-/herself can benefit from a better and real-time focus on ProM’s?

•Value-based health-care as merely a stepping stone towards transparent, data-driven, subjective well-being

Silvia Bakkers, J&J, NetherlandsDirector Value-Based Healthcare

10:20 Morning coffee & networking

11:00 PAYER'S VIEW: Outcomes-based people-centric healthcare – success factors

•evidence-based strategies to measure outcomes•Including the patient's voice in the payer's decision•Tackling adherence & treatment cost-effectiveness•Steps to achieve shared goals

11:30 HCP'S VIEW: Patient involvement in clinical research is essential to create successful and relevant lifestyle strategies

•exploring real-world scientific research•A greater understanding of patient needs

allows the development of lifestyle strategies to empower patients with the evidence to make informed lifestyle choices

•Benefits of involving patients in the design of trials

Robert ThomasCambridge University Hospitals, UKConsultant Oncologist

12:00 BREAKOUT DISCUSSION: Industry & patient views: The way forward - Effective tools & approaches for better patient outcomes

•Patient-centric approaches to improving patient outcomes

•Developing a business model for evidence-based patient support offerings

•Measuring the impact on patient outcomes, society and business value

•Patient involvement at protocol assessments at fDA/eMA

•Strategies for improvement

Lode Dewulf, Belgium, Former Chief Medical Affairs Officer and Chief Patient Affairs Officer

12:30 luncheon

www.fleming.events tel.: +421 257 272 232 email: monica.jones@fleming.events

DAY 116 May 2018

Value-based partnering

14:00 Patients as partners

•Co-creation & increasing patient voice in decision making

•overcoming compliance and legal challenges (transparency, data privacy) – tips

•Collaboration perspective – what kind of new partnership is driving progress for real-world patient impact?

•examples – industry, regulatory and patient views

Alexandra Moutet, UCB, Belgium Global Head of Patient Affairs

Marleen KaateePSC Patients Europe, NetherlandsFounding President

15:00 Afternoon tea & networking

15:30 Maximizing the patient experience across the healthcare as a whole - Where and how do all stakeholders step in?

•Sharing responsibility – taking charge of your health

•Collaborative work with patients & families – communication and interventions based on a patient type

•empowering the patients for optimal treatment decisions

•The real informed consent•opportunities for improved adherence and

outcomes – success factors for optimizing rW use of medicines

•examples – a doctor's, nurse's, pharmacist's and industry view

Martynas Gedminas, LithuaniaChairman Junior Doctors Association

Geoff Rollason, Pfizer, UKPatient Experience & Service Director Oncology

16:30 Value-based Patient Support Programs

•featuring industry and patient views•Designing & implementing sustainable patient

support programs•PSP ownership•How to partner with other stakeholders for

optimal implementation•Planning & execution of PSP – driving awareness

about a PSP•Measuring the value of PSPs•Patient feedback – what does a PSP bring to me? •results & outcomes achieved

Grainne Crowley, Biogen, Belgium, Head Patient Advocacy Europe & Canada (to be confirmed)

Jessica Leygues, Celgene, France, Patient Associations and Patient Institutional Programs Manager

Veerle Aertsen, EUPATI Fellow, Belgium Co-chair and spokesperson for EupatiExpert Parkinson's Disease Patient

Wendy Olsder, NetherlandsBoard Member of Youth-R-Well.com and representative of Young PARE

17:30 BREAKOUT DISCUSSION: Action planning for multi-stakeholder collaboration for better outcomes

•Primary and secondary non-adherence, reasons for non-adherence

•The most effective strategies for working together with other stakeholders to improve outcomes

•PSP ownership – accountability and responsibilities/roles of all stakeholders

•Measuring the value of PSPs

18:00 Evaluation of Day 1 and conclusions Speakers & delegates are cordially invited to attend a networking Cocktail Reception

www.fleming.events tel.: +421 257 272 232 email: monica.jones@fleming.events

DAY 217 May 2018

8:30 Registration & morning coffee

9:00 Opening remarks from the chair

Effective Patient Engagement

9:10 On-stage interview

Marleen Kaatee, PSC Patients Europe, Netherlands, Founding President

9:30 THE YOUTH FACTOR: The value of engaging with the next generation of empowered patients

•Understanding patient engagement•Creating a culture of engagement in young

adults and children•Project: ePf’s STYPA

Andreas Christodoulou, EPF's Youth Group, Cyprus, President

10:10 CASE STUDY: Patient engagement in rare diseases R&D

•Patient centric approach to r&D•opportunities and challenges for engagement-

a young biotech perspective•examples of methods for effective patient

engagement

Annamarie Dillon, ProQR Therapeutics, Netherlands, Senior Director, Patient & Medical Community Engagement

10:40 Morning coffee & networking

11:10 CODE OF CONDUCT: Cooperation with patients and patient organisations

•Compliance, governance and legal framework of patient engagement

•Ways to engage - avenues, methods and strategies

•Strategies for patient activation & motivation

Stefan Florentinus, AbbVie, NetherlandsMedical Director, Chair of the project group at Duch Association Innovative Medicine

11:40 CASE STUDY: Key learnings from a patient-centric activity in the development and lifecycle of medicines led by Santhera Pharmaceuticals

•Defining ways to engage with patient advocacy groups that represent Duchenne Muscular Dystrophy (DMD)

•Identifying projects that serve the DMD patient groups needs

•Impact of an International DMD Patient Group advisory board on company decisions

•final recommendations transferable across rare diseases

Vanessa Ferreira, Santhera, Switzerland Head Patient Advocacy Europe

12:00 BREAKOUT DISCUSSION: Engaging & empowering patients

•navigating patients in a fragmented environment•The new role of patients •Shaping the future

Ruth Wilson, Teva, Netherlands, Global Head of Patient AdvocacyAnna Szopa, J&J, Poland, Head of Patient Engagement & AdvocacyAndreas Christodoulou, EPF's Youth Group, Cyprus, PresidentAnnamarie Dillon, ProQR Therapeutics, Netherlands, Senior Director, Patient & Medical Community Engagement Wendy Olsder, Netherlands, Board Member of Youth-R-Well.com and representative of Young PARE

www.fleming.events tel.: +421 257 272 232 email: monica.jones@fleming.events

DAY 217 May 2018

12:30 luncheon

13:40 CASE STUDY: Skills4Adherence Project – Improving patient adherence in the elderly

•Interventions to improve patient adherence in the elderly

•Interventions to prevent polytherapy in the elderly

•Motivating the elderly to take action to improve adherence to therapeutic recommendations and to prevent polytherapy

Przemyslaw Kardas, Medical University of Lodz, Poland, Head of the Department, Department of Family Medicine

14:20 CASE STUDY: Behavioral science project - Improving medication adherence

•Driving health behavior change•new trigger for patient compliance•Mutually beneficial business model – results

achieved

Søren Skovlund, Denmark, Chief Patient Officer, Drugstars

Senior Research Scientist, Aalborg University, Denmark

14:40 Digital adherence solutions

•engagement possibilities brought by digital solutions

•Utilizing real-time data•Utilizing digital tools in clinical research and

clinical practice to inform decision-making•Tailoring the program for each patient

15:00 Afternoon tea & networking

15:30 CASE STUDY: Adding value to the patient experience

•Patient preferences & benefit-risk assessments•Patient journey mapping•Measuring and re-shaping patient experience

Ana Maria Arboleda, Teva, Spain, Director of European Operations, Patient Solutions

Veerle Aertsen, EUPATI Fellow, Belgium Co-chair and spokesperson for EupatiExpert Parkinson's Disease patient

16:00 How digital & mobile improve the patient experience

•Leveraging digital and mobile technologies to better connect with and engage patients

•Balancing technology with the personal touch•Digital health & AI•Utilizing big data and analytics for better

& personalized patient services

16:30 WRAP-UP DISCUSSION: Joining forces and integrated approach

•revisiting the outputs from previous breakout discussions

•Defining top priority actions•Concrete actions & steps for the upcoming year•Defining measurement of the progress related

to key actions & to the overall aim of improving real world patients outcomes and real world use of medicines

17:00 Evaluation of the day & closing remarks from the chair

I would like to thank everyone who has helped with the research and organization of this event, especially the speakers, for their support and commitment.

Dasa Janosikova, Production Manager Life Sciencesdasa.janosikova@fleming.events.com

www.fleming.events tel.: +421 257 272 232 email: monica.jones@fleming.events

Darius Slavik | MD, Corporate Learning Programs

T: +421 257 272 180 | M: +421 918 447 166

CONTACT US TO GET STARTED

APPLY! Get the real ROI by achieving the highest implementation rate of your learning

CUSTOMIZE!in the privacy of your organization

ENGAGE! Make your onboarding and training count with our interactive e-learning programs

This one’s

for you

Why choose our corporate learning programs

Only

CORPORATE LEARNING

In-houseTraining

BlendedLearning e-Learning

Custom Content

e- Learning

Complex Learning Experience

Terms and Conditions:1. PAYMenT TerMS. Fleming Events, s.r.o. (hereinafter as “fe”) requires the full payment of the invoiced amount within 7 working days

from the issue date of the invoice. fe reserves the right to refuse entry to any client who does not pay the invoice in full and on time. If the payment is not received on fe’s account on the seventh day from the date of the issue of the invoice, fe is entitled to charge the Client an overdue interest of 5% p.a. for every day, for which the Cleint’s payment is overdue. The registration fee includes: conference documentation, admission to all conference sessions, lunches and refreshments, admission to networking social breaks during the event. The registration fee does not include: travel, hotel accommodation, transfers or insurance.

2. HoTeL ACCoMMoDATIon. overnight accommodation is not included in the registration fee. A reduced rate may be available for fe’s clients at the hotel hosting the event. The reservation form will be sent to the client after the venue has been confirmed, but no later than one month before the event begins.

3. CAnCeLLATIon BY CLIenT. The client has the right to cancel his/her participation in the event. Cancellation must be received by fe in writing, either by mail, email or fax. If the client cancels with more than one month’s advance notice before the start of the event, fe shall be entitled to retain and charge 50% of the total invoiced amount. If the client cancels with one month’s (or less) advance notice, or fails to attend the event, then the client shall not be entitled to any refund nor any discount. Client’s failure to attend the event does not cancel, decrease or in any matter waives the client’s obligation to fully pay the fee invoiced to the client by fe.

4. CAnCeLLATIon BY fe. While every reasonable effort is made to adhere to the advertised program, circumstances out of the control of fe can arise, which may cause changes in the program, including but not limited to changes in the content, date(s), location or venue, or special features of the planned event. Such circumstances include but are not limited to acts of terrorism, war, extreme weather conditions, compliance with government requests, orders and legal requirements, failure of third party suppliers to timely deliver, and failure to register the minimum targeted amount of attendees for a given event. fe reserves the right to change the content, date(s), location or venue and/or special features of an event, to merge the event with another event, or to postpone it or cancel it entirely as appropriate under the circumstances. Client agrees that fe shall not be liable for any cost, damage or expense which may be incurred by client as a consequence of the event being changed, merged with another event, postponed or cancelled and client agrees to hold fe harmless and to indemnify fe for any liability caused by any such changes, mergers, postponements or cancellations to the Client.

5. CAnCeLLATIon of THe eVenT. In case fe cancels the event, fe may offer the client a full credit up to the amount actually paid by the client to fe. This credit shall be valid for up to one year from the issue date of the invoice to attend any of fe’s events. The client shall not be entitled to this credit as a contractual right.

6. CLIenTS IDenTIfICATIon InforMATIon. By signing of this sales contract and these terms and conditions the client gives full right to fe to share the client’s identification information such as, but not limited to, client’s name, address, email addresses, phone numbers and names of representatives with third parties, which participated on the same event as the client.

7. GoVernInG LAW. This contract shall be governed and construed in accordance with the laws of the Slovak republic (not including its conflict of laws provisions). Any disputes arising out of this contract shall be brought before the courts of the Slovak republic situated in the city of Bratislava in the Slovak republic.

8. InDeMnIfICATIon. To the fullest extent permitted by the law, you agree to protect, indemnify, defend and hold harmless fe, its owners, managers, partners, subsidiaries, affiliates, officers, directors, employees and agents, from and against any and all claims, losses or damages to persons or property, governmental charges or fines, penalties, and costs (including reasonable attorney’s fees) (collectively “the Claims”), in any way arising out of or relating to the event that is the subject of this contract, and regardless of negligence, included but not limited to, Claims arising out of the negligence, gross negligence or intentional misconduct of fe employees, agents, contractors, and attendees; provided, however, that nothing in this indemnification shall require you to indemnify fe Indemnified parties for that portion of any Claim arising out of the sole negligence, gross negligence or intentional misconduct of the fe parties.

9. oTHer CUrrenCIeS. In case that client requests payment in other than fe’s official currency (eUr), fe reserves the right to apply 8% currency risk surcharge to the actual exchange rate.

10. oTHer ConDITIonS. Any terms or conditions contained in the client’s acceptance which contradict or are different from the terms and conditions of this registration document shall not become part of the contract unless individually negotiated with fe and expressly accepted by fe.

Patient Engagement & Experience 16 & 17 May 2018 | Amsterdam

27 € admin istration charge and 21% Ditch VAT will be appliedPayment is required within 7 working days

If you wish to pay in USD ($) or GBP (£) please contact us for more details.

In the name of fleming events, s.r.o. I hereby declare fleming events, s.r.o. will adhere to this sales contract & terms & conditions

eDUArD VACULA, Director

Under european Union and Dutch tax regulations delegates are required to pay VAT in any conference taking place in the netherlands. Delegates may be entitled to reclaim this cost.

Sales ContractPLEASE COMPLETE THIS FORM AND SEND IT BACK TO:

PH O N E: +421 2 57 272 232E-MAIL TO: monica.jones@fleming.events

OR FAX: + 421 255 644 490

Client Identification Details(Please complete form IN CAPITAL LETTERS for each client)

Ms Mrs Mr Surname:

Name:

Job Title:

Email:

Ms Mrs Mr Surname:

Name:

Job Title:

Email:

Ms Mrs Mr Surname:

Name:

Job Title:

Email:

Company/Organisation Details

Name:

VAT Number: (VAT No. for EU members / Tax Number for non-EU members)

Contact person:

Email:

Address:

City:

Country:

Phone:

Nature of business:

Website:

Payment MethodPlease debit my

Visa Eurocard / Mastercard Amex Diners club Card Billing Address:

Street:

City: Post/Zip Code

Card Holder´s Name:

Card Holder´s Signature:

Card Number:

Visa CVC Number or Eurocard/Mastercard CVV Number or Amex DBC

3 or 4 digit code on the back or front of the card

Valid from Expiry Date

I agree to Fleming Events, s.r.o. debiting my card.

Authorization and Acceptance of Sales Contract & Terms & ConditionsI hereby declare I am authorised to sign this contract and terms & conditions in the name of the company/organisation:

Name:

Date:

Signature: Booking is invalid without a signature

Code: BA LS 208_M

Agreed Price of the Service

€ 1595

€ 1395

Industry Professional

Early Bird Offer per delegate

per delegate

€ 699

€ 3099

Public Sector

Consultant / Solution Provider

per delegate

per delegate

(universities, governmental and non-profit organizations)

(Valid till 31st January 2018)